Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
Gilead Sciences: Seriously Undervalued At Peak Pessimism
01:31pm, Tuesday, 28'th May 2024
On April 26, Gilead Sciences published financial results for the first quarter of 2024, which were better than I expected. So, total sales of oncology drugs amounted to $789 million, up about 18% year
2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years
09:45am, Tuesday, 28'th May 2024
CVS Health provides a comprehensive suite of interrelated healthcare services. Gilead Sciences' sales are growing steadily, and newer approvals should help.
Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies Against Novel Targets and Target Pairs
07:00am, Tuesday, 28'th May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., announced today that it has entered into a strategic collaboration agreement with Gilead Sciences, Inc., to discover and de
Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish
01:07pm, Monday, 27'th May 2024
At this point, Gilead Sciences could only be fairly valued with trading for 10 times free cash flow. With Veklury sales close to a bottom, Gilead Sciences might finally start growing its top line agai
Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows
01:45am, Monday, 27'th May 2024
Gilead is sitting at one of the lowest valuations in the Big Pharma sector, with a high and sustainable 4.6% dividend yield available for new buyers. The stock has an enviable track record of rising s
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
12:00pm, Friday, 24'th May 2024
The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting. Companies such as GSK, Moderna, BioNTech, Gilead, and many others will reporting their progress.
Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
07:00am, Thursday, 23'rd May 2024
Gilead Sciences has a 4.5% yield. The company has struggled with declining profits and sales in recent years. The company's growth potential lies in its HIV and oncology treatments, but it faces compe
3 Biotech Stocks to Buy Now: May 2024
10:48am, Wednesday, 22'nd May 2024
While it tends to fly under the radar for many people, the biotech industry has seen a resurgence in investor interest over the last couple of years. While there could be several reasons for this, s
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
08:30am, Wednesday, 22'nd May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8,
3 Cheap and Dependable Dividend-Growth Stocks to Buy
11:52am, Tuesday, 21'st May 2024
These dividend growers look undervalued today.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
10:01am, Tuesday, 21'st May 2024
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead (GILD) Announces Positive Interim Results on PBC Drug
11:46am, Monday, 20'th May 2024
Gilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in liver disease progression and reduced itching in primary biliary cholangitis study.
Gilead (GILD) Announces Positive Interim Results on PBC Drug
12:00am, Monday, 20'th May 2024
Gilead Sciences, Inc. (GILD Quick QuoteGILD - Free Report) announced positive interim results from the ongoing ASSURE study on pipeline candidate seladelpar.ASSURE is an open-label study evaluating th
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
10:09am, Tuesday, 14'th May 2024
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upc
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 10'th May 2024
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
